A study that examined the relationship between two cerebrospinal fluid proteins associated with Alzheimer disease in clinically and cognitively normal older patients suggests that amyloid-β (Αβ)-associated clinical decline was linked to the presence of elevated phospho-tau (p-tau).

Persistent ocular tremors that prevent eye stability during fixation appear to be common among patients with Parkinson disease (PD) suggesting that precise oculomotor testing could provide an early physiological biomarker for diagnosing PD.

Immunotherapy with the antibody bapineuzumab in patients with mild to moderate Alzheimer disease resulted in decreases in a cerebrospinal fluid biomarker, which may indicate downstream effects on the degenerative process.

A meta-analysis of previously published studies found that the ratio of blood plasma amyloid-β (Aβ) peptides Aβ42:Aβ40 was significantly associated with development of Alzheimer disease and dementia.

Early-initiated immunotherapy appears to be associated with improved seizure outcomes among patients with autoimmune epilepsy.